ERS Genomics and Université de Montréal sign CRISPR/Cas9 license agreement License agreement provides Université de Montréal access to CRISPR gene editing technology for use across its platform services   Dublin, Ireland, and Montreal, Canada, 01 October 2024: ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and Université de Montréal (‘UdeM’), a leading Canadian research institution renowned for scientific innovation and technology transfer, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants the university access to ERS’ CRISPR/Cas9 patent portfolio – including enabling the launch of two CRISPR/Cas9 screening facility platforms at UdeM’s Institute for Research in Immunology and Cancer.